← Back to Search

Novel spectacle lens design

New Glasses for Nearsightedness (CYPRESS Trial)

N/A
Waitlist Available
Research Sponsored by SightGlass Vision, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 72 months
Awards & highlights

CYPRESS Trial Summary

This trial will test if a new type of glasses can help reduce the progression of juvenile myopia, and if it is safe to use.

Who is the study for?
This trial is for kids who were in the CYPRESS study and can commit to wearing special glasses for up to 3 years, at least 10 hours a day. They shouldn't have been out of the previous study for over 30 days and must not wear contact lenses during this time. Parents or guardians need to consent.Check my eligibility
What is being tested?
The trial tests SightGlass Vision Diffusion Optics Technology (DOT) Spectacles' long-term ability to slow down worsening near-sightedness in children compared with regular glasses, monitored over a period of three years.See study design
What are the potential side effects?
Specific side effects are not listed, but as with any eyewear, there may be discomfort or adjustment issues. The spectacles are non-invasive so significant side effects are unlikely.

CYPRESS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~72 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 72 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Spherical equivalent refraction (SER)
Secondary outcome measures
Axial length
SER

CYPRESS Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: CYPRESS Extension Test ArmExperimental Treatment1 Intervention
Single vision, impact resistant spectacle lenses; CYPRESS Test Arm 1 and CYPRESS Test Arm 2 will move into CYPRESS Extension Test Arm
Group II: CYPRESS Extension Control ArmPlacebo Group1 Intervention
Single vision, impact resistant spectacle lenses; CYPRESS Control Arm remains in control lenses as the CYPRESS Extension Control Arm
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Novel spectacle lens design
2022
N/A
~60

Find a Location

Who is running the clinical trial?

SightGlass Vision, Inc.Lead Sponsor
10 Previous Clinical Trials
893 Total Patients Enrolled

Media Library

SightGlass Vision Diffusion Optics Technology (DOT) Spectacles (Novel spectacle lens design) Clinical Trial Eligibility Overview. Trial Name: NCT04947735 — N/A
Near-sightedness Research Study Groups: CYPRESS Extension Control Arm, CYPRESS Extension Test Arm
Near-sightedness Clinical Trial 2023: SightGlass Vision Diffusion Optics Technology (DOT) Spectacles Highlights & Side Effects. Trial Name: NCT04947735 — N/A
SightGlass Vision Diffusion Optics Technology (DOT) Spectacles (Novel spectacle lens design) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04947735 — N/A
Near-sightedness Patient Testimony for trial: Trial Name: NCT04947735 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the total number of sites administering this trial?

"Thirteen clinical sites are currently accepting participants for this trial, including cities such as Memphis, Pittsburg and Raytown. To make the experience more convenient, it's advisable to select a location closest you in order to minimize travelling requirements."

Answered by AI

Are there any open enrolment opportunities for this trial currently?

"Clinicaltrials.gov indicates that this trial, which was initially published on July 19th 2021 and last modified on September 28th 2022, is not currently enrolling patients. However, 98 other studies are actively recruiting participants at the moment."

Answered by AI

Does this trial offer participation to those below the age of twenty?

"Currently, the trial is targeting patients between 6 and 17 years of age."

Answered by AI

Who is the optimal candidate for enrollment in this research study?

"This medical trial seeks 200 participants aged between 6 and 17 who are currently living with myopia. In order to be eligible, the subjects must commit to wearing the assigned spectacles for at least 10 hours daily (with exceptions made for hazardous or impossible activities), as well as participating in this study up until its completion over a period of three years without utilizing contact lenses."

Answered by AI

Who else is applying?

What state do they live in?
New York
Tennessee
How old are they?
< 18
What site did they apply to?
Advanced Eyecare PC
Dunes Eye Consultants
William J Bogus, OD, FAAO
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

I am concerned for son's poor vision at this early age. I like doing my part to help improve medical treatment. I find I’m having more issues reading up close.
PatientReceived 2+ prior treatments
My Retinologist informed me I have macular degeneration, and I’d like to try something that would help this.
PatientReceived 1 prior treatment
Recent research and studies
clinicaltrials.govStudy
CYPRESS Efficacy and Safety Study Extension
2021. "CYPRESS Efficacy and Safety Study Extension". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04947735.
All > Myopia
~53 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top